Global Clinical Trials Outsourcing Market Share, Size, Trends, Industry Analysis Report, By End-Use, By Therapeutics Area, By Service Type, By Application, By Region, Segment Forecast, 2024 - 2031
- Published Date : 2024-09-18
- Pages : 100
- Report Id : 40447
- Categories : Healthcare
This report describes the global market size of Clinical Trials Outsourcing from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 26.2%% from 2024 to 2031.
Due to the COVID-19 pandemic, the global market for Clinical Trials Outsourcing estimated at US 25.9 $ billion in the year 2023, is projected to reach a revised size of US 52.6$ million by 2031, growing at a CAGR of 26.2% during the forecast period 2024-2031.
Clinical trials outsourcing refers to hiring external organizations or service providers to conduct or manage various aspects of clinical trials. Pharmaceutical companies, biotechnology firms, and medical device companies often outsource parts of their clinical trials to specialized third-party organizations, such as Contract Research Organizations (CROs), to handle tasks like patient recruitment, data management, regulatory compliance, and clinical monitoring. Outsourcing clinical trials allows companies to leverage the expertise, infrastructure, and resources of these external providers, often resulting in cost savings, increased efficiency, and the ability to simultaneously conduct trials in multiple geographic regions. This approach is particularly beneficial for managing complex, large-scale, or global clinical trials where in-house resources may be limited.
For geography segment, regional supply, demand, major players, price is presented from 2019 to 2031. This report cover following regions:
North America
Asia-Pacific
Europe
Middle East and Africa
South America
The key countries for each regions are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For competitor segment, the report include global key players of Clinical Trials Outsourcing as well as some small players. The information for each competitor include:
Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share
By Phase of Clinical Trial
Phase I
Phase II
Phase III
Phase IV
The clinical trials outsourcing market involves various phases, each with distinct requirements and objectives. Phase I trials, focusing on safety and dosage, are often outsourced to specialized Contract Research Organizations (CROs) to leverage their expertise in early-stage drug development and to manage the complex logistics of initial human testing. Phase II trials, which assess efficacy and side effects, frequently see increased outsourcing as sponsors seek CROs with specific therapeutic expertise and the capacity to handle larger patient populations. Phase III trials, the most extensive phase, involve large-scale testing to confirm effectiveness and monitor adverse reactions across diverse populations. Outsourcing during this phase is critical for managing the scale and complexity of the trials, with CROs providing extensive resources, global reach, and specialized data management capabilities. Phase IV trials, conducted post-marketing to gather additional information on long-term effects and optimal use, are also commonly outsourced. CROs play a key role in monitoring real-world efficacy and safety, ensuring compliance with regulatory requirements, and managing post-market surveillance. Overall, outsourcing across all phases of clinical trials helps streamline processes, reduce costs, and enhance access to specialized expertise, making it a vital component of the drug development lifecycle.
By Service Type
Preclinical Services
Clinical Development Services
Contract Research Organizations (CROs)
Contract Manufacturing Organizations (CMOs)
Consulting Services
The clinical trials outsourcing market includes several key service types that streamline drug development. Preclinical services involve early-stage research and testing on non-human subjects to assess safety and efficacy before human trials. Clinical development services cover the full range of activities from Phase I to Phase IV trials, including patient recruitment, monitoring, and data management. Contract Research Organizations (CROs) provide specialized support for managing and conducting clinical trials, offering expertise in regulatory compliance, clinical operations, and data analysis. Contract Manufacturing Organizations (CMOs) handle the production of clinical trial materials, including the synthesis and formulation of drugs, ensuring they meet quality standards and regulatory requirements. Lastly, consulting services offer strategic guidance on trial design, regulatory strategy, and market access, helping sponsors navigate complex clinical development challenges. Together, these services enable efficient and effective drug development by leveraging external expertise and resources.
By Therapeutic Area
Oncology
Cardiology
Neurology
Endocrinology
Infectious Diseases
Others
The clinical trials outsourcing market is shaped by various therapeutic areas, each requiring specialized expertise. Oncology trials are highly complex, often involving extensive patient monitoring and advanced data analysis, leading sponsors to outsource to CROs with cancer research expertise. Cardiology trials focus on heart diseases, necessitating specialized knowledge in cardiovascular health and regulatory compliance, often provided by niche CROs.
Neurology trials, dealing with conditions of the nervous system, require precise diagnostic tools and patient management strategies, prompting outsourcing to experts in neurological research. Endocrinology trials, which study hormone-related conditions, benefit from CROs experienced in endocrine disorders and hormone therapies. Infectious diseases trials are critical for developing treatments for diseases like HIV and malaria, leveraging CROs with experience in managing large-scale studies and global logistics. Others encompass a range of therapeutic areas including rare diseases and metabolic disorders, each requiring tailored approaches and specialized expertise. Outsourcing in these areas ensures access to the necessary resources and knowledge to conduct effective and compliant clinical trials.
By Application
Small Molecules
Monoclonal Antitodes
vaccine
Cell & Gene Theraphy
Other Applications
The clinical trials outsourcing market supports a diverse range of applications, each with unique requirements and complexities. Small molecules represent a significant area of drug development, involving trials to test new chemical compounds for efficacy and safety. Outsourcing in this area typically includes services for drug formulation, preclinical testing, and clinical trials, leveraging CROs with expertise in pharmaceutical development. Monoclonal antibodies are a major focus due to their role in treating various diseases, including cancers and autoimmune conditions. Trials for these biologics often require specialized facilities for production and testing, leading sponsors to partner with CROs skilled in biopharmaceutical research and development. Vaccines require extensive clinical trials to ensure efficacy and safety before approval. Outsourcing for vaccine development often involves CROs with experience in large-scale trials, regulatory compliance, and global distribution.
Cell and gene therapy represent cutting-edge treatments with complex manufacturing and regulatory requirements. Trials in this area involve specialized CROs that handle advanced cell processing, genetic modifications, and patient monitoring. Other applications include a broad spectrum of innovative therapies and technologies, such as regenerative medicine and novel drug delivery systems. Outsourcing in these areas provides access to specialized expertise and advanced technologies, essential for successful clinical development and market introduction.
End User
Pharmaceutical Companies
Biotechnology Companies
Medical Device Companies
Academic and Research Institutions
The clinical trials outsourcing market serves a diverse set of end users, each leveraging external expertise to enhance their development processes. Pharmaceutical companies frequently outsource clinical trials to access specialized knowledge and manage large-scale studies efficiently, focusing on drug development and regulatory compliance. Biotechnology companies, involved in developing innovative therapies and biologics, rely on outsourcing to handle complex trials and navigate regulatory requirements, ensuring effective and timely product development. Medical device companies outsource clinical trials to test new devices, gather clinical data, and ensure compliance with regulatory standards, benefiting from CROs that offer expertise in medical device testing and evaluation. Academic and research institutions often collaborate with CROs to conduct clinical studies as part of research initiatives, leveraging external resources to support high-quality trials and data analysis while focusing on advancing scientific knowledge. Together, these end users utilize outsourcing to streamline trial processes, access specialized resources, and achieve their development and research goals.
Key Players
Pharmaceutical Product Development
Thermo Fisher Scientific
Charles River Laboratories International.
Syneos Health.
SGS SA.
PAREXEL International Corporation
Wuxi AppTec
Chiltern International Ltd (Laboratory Corporation of America)
Eli Lilly and Company
Novo Nordisk A/S
Clinipace (Caidya)
Please ask for sample pages for full companies list
Base Year: 2023
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2031
Any special requirements about this report, please let us know and we can provide custom report.
TABLE OF CONTENTS
Market Taxonomy
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis and Recommendations
1.3. RA Analysis and Recommendations
2. Market Introduction
2.1. Market Definition
3. Market Background
3.1. Parent/Associated Market Overview
3.1.1.Clinical Trials Outsourcing Outlook
3.1.2.Clinical Trials Outsourcing Overview
3.2. Effect of Covid-19 Impact
3.3. Macro-Economic Overview
3.3.1. GDP Growth
3.3.2. Retail Industry Growth
3.4. Pricing Analysis
3.5. Challenges related to adoption of Clinical Trials Outsourcing
3.6. Regulations of Clinical Trials Outsourcing
3.7. Forecast Factors: Relevance and Impact
3.8. Market Dynamics
3.8.1. Drivers
3.8.2. Restraints
3.8.3. Opportunity
3.8.4. Trends
3.8.5. SWOT Analysis
4. Market Forecast
4.1. Market Value Projections
4.2. Market Size Projections
4.3. Y-o-Y Projections
4.4. Absolute Opportunity Analysis
5. Global Clinical Trials Outsourcing Value Chain Analysis
5.1.Clinical Trials Outsourcing Value Chain
5.1.1. List of Raw Material Suppliers
5.1.2. List of Clinical Trials Outsourcing Manufacturers
5.1.3. List of Segment
6. Global Clinical Trials Outsourcing Analysis By Phase of Clinical Trial
6.1. Introduction
6.1.1. Market Value Share Analysis By Phase of Clinical Trial
6.1.2. Y-o-Y Growth Analysis By Phase of Clinical Trial
6.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Phase of Clinical Trial
6.3. Market Attractiveness Analysis Age Group
7. Global Clinical Trials Outsourcing Analysis By Service Type
7.1. Introduction
7.1.1. Market Value Share Analysis By Service Type
7.1.2. Y-o-Y Growth Analysis By Service Type
7.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Service Type
7.3. Market Attractiveness Analysis By Service Type
8. Market Structure Analysis
8.1. Market Analysis by Tier of Companies
8.1.1. By Large, Medium, and Small
8.2. Market Concentration
8.2.1. By Top 5 and by Top 10
8.3. Type ion Capacity Share Analysis
8.3.1. By Large, Medium, and Small
8.3.2. By Top 5 and Top 10
8.4. Technology Roadmap
9. Competition Analysis
9.1. Competition Dashboard
9.2. Company Profiles (15 Companies)
9.2.1. Pharmaceutical Product Development
9.2.1.1. Overview
9.2.1.2. Type Portfolio
9.2.1.3. Financial Overview
9.2.2. Thermo Fisher Scientific
9.2.2.1. Overview
9.2.2.2. Type Portfolio
9.2.2.3. Financial Overview
9.2.3. Johns Hopkins Medicine
9.2.3.1. Overview
9.2.3.2. Type Portfolio
9.2.3.3. Financial Overview
9.2.4. Syneos Health.
9.2.4.1. Overview
9.2.4.2. Type Portfolio
9.2.4.3. Financial Overview
9.2.5. SGS SA.
9.2.5.1. Overview
9.2.5.2. Type Portfolio
9.2.5.3. Financial Overview
9.2.6. PAREXEL International Corporation
9.2.6.1. Overview
9.2.6.2. Type Portfolio
9.2.6.3. Financial Overview
9.2.7. Wuxi AppTec
9.2.7.1. Overview
9.2.7.2. Type Portfolio
9.2.7.3. Financial Overview
9.2.8.Chiltern International Ltd (Laboratory Corporation of America)
9.2.8.1. Overview
9.2.8.2. Type Portfolio
9.2.8.3. Financial Overview
9.2.9. Eli Lilly and Company
9.2.9.1. Overview
9.2.9.2. Type Portfolio
9.2.9.3. Financial Overview
9.2.10. Novo Nordisk A/S
9.2.10.1. Overview
9.2.10.2. Type Portfolio
9.2.10.3. Financial Overview
9.2.11. Clinipace (Caidya)
9.2.11.1. Overview
9.2.11.2. Type Portfolio
9.2.11.3. Financial Overview
9.2.12. COMPANY12
9.2.12.1. Overview
9.2.12.2. Type Portfolio
9.2.12.3. Financial Overview
9.2.13. COMPANY13
9.2.13.1. Overview
9.2.13.2. Type Portfolio
9.2.13.3. Financial Overview
9.2.14. COMPANY14
9.2.14.1. Overview
9.2.14.2. Type Portfolio
9.2.14.3. Financial Overview
9.2.15. COMPANY15
9.2.15.1. Overview
9.2.15.2. Type Portfolio
9.2.15.3. Financial Overview
10. Global Clinical Trials Outsourcing Analysis By Region
10.1. Introduction
10.1.1. Market Value Share Analysis By Region
10.1.2. Y-o-Y Growth Analysis By Region
10.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Region
10.2.1. North America
10.2.2. Middle East and Africa
10.2.3. South America
10.2.4. Asia-Pacific
10.2.5. Others
10.3. Current Market Size (USD Mn) Forecast 2023-2030 By Region
10.3.1. North America
10.3.2. Middle East and Africa
10.3.3. South America
10.3.4. Asia-Pacific
10.3.5. Others
10.4. Market Attractiveness Analysis By Region
11. North America Clinical Trials Outsourcing Analysis
11.1. Introduction
11.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
11.2.1. U.S.
11.2.2. Canada
11.2.3. Mexico
11.2.4. Rest of North America
11.3. Current Market Size (USD Mn) Forecast 2023-2030 By Country
11.3.1. U.S.
11.3.2. Canada
11.3.3. Mexico
11.3.4. Rest of North America
11.4. Historical Market Size (USD Mn) Analysis 2018-2022 By Phase of Clinical Trial
11.5. Current Market Size (USD Mn) Forecast 2023-2030 By Phase of Clinical Trial
11.6. Historical Market Size (USD Mn) Analysis 2018-2022 By Service Type
11.7. Current Market Size (USD Mn) Forecast 2023-2030 By Service Type
12. South America Clinical Trials Outsourcing Analysis
12.1. Introduction
12.2. Regional Pricing Analysis
12.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
12.3.1. Brazil
12.3.2. Argentina
12.3.3. Rest of South America
12.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of South America
12.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Phase of Clinical Trial
12.6. Current Market Size (USD Mn) Forecast 2023-2030 By Phase of Clinical Trial
12.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Service Type
12.8. Current Market Size (USD Mn) Forecast 2023-2030 By Service Type
13. Europe Clinical Trials Outsourcing Analysis
13.1. Introduction
13.2. Regional Pricing Analysis
13.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
13.3.1. Germany
13.3.2. Italy
13.3.3. France
13.3.4. Spain
13.3.5. U.K.
13.3.6. Rest of Europe
13.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
13.4.1. Germany
13.4.2. Italy
13.4.3. France
13.4.4. Spain
13.4.5. U.K.
13.4.6. Rest of Europe
13.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Phase of Clinical Trial
13.6. Current Market Size (USD Mn) Forecast 2023-2030 By Phase of Clinical Trial
13.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Service Type
13.8. Current Market Size (USD Mn) Forecast 2023-2030 By Service Type
14. Middle East and Africa Clinical Trials Outsourcing Analysis
14.1. Introduction
14.2. Regional Pricing Analysis
14.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
14.3.1. Saudi Arabia
14.3.2. U.A.E.
14.3.3. South Africa
14.3.4. Turkey
14.3.5. Rest of Middle East and Africa
14.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
14.4.1. Saudi Arabia
14.4.2. U.A.E.
14.4.3. South Africa
14.4.4. Turkey
14.4.5. Rest of Middle East and Africa
15. Asia-Pacific Clinical Trials Outsourcing Analysis
15.1. Introduction
15.2. Regional Pricing Analysis
15.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
15.3.1. China
15.3.2. India
15.3.3. Japan
15.3.4. South Korea
15.3.5. Singapore
15.3.6. Australia and New Zealand
15.3.7. Rest of Asia-Pacific
15.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
15.4.1. China
15.4.2. India
15.4.3. Japan
15.4.4. South Korea
15.4.5. Singapore
15.4.6. Australia and New Zealand
15.4.7. Rest of Asia-Pacific
i. Research Methodology
ii. Assumptions & Acronyms
LIST OF FIGURES
Figure 01: Global Clinical Trials Outsourcing, BPS Analysis,By Phase of Clinical Trial, 2018(H), 2023(E) & 2030(F)
Figure 02: Global Clinical Trials Outsourcing, Y-O-Y Growth,By Phase of Clinical Trial, 2020(A) - 2030(F)
Figure 03: Global Clinical Trials Outsourcing Attractiveness Analysis, By Phase of Clinical Trial (2020)
Figure 04: Global Clinical Trials Outsourcing, BPS Analysis, By Service Type, 2018(H), 2023(E) & 2030(F)
Figure 05: Global Clinical Trials Outsourcing, Y-O-Y Growth, By Service Type, 2018(H) - 2030(F)
Figure 06: Global Clinical Trials Outsourcing Attractiveness Analysis, By Service Type
Figure 07: Global Clinical Trials Outsourcing, Value Analysis, By Phase of Clinical Trial, 2018(H)-2030(F)
Figure 08: Global Clinical Trials Outsourcing, Value Analysis, by By Service Type, 2018(H)-2030(F)
Figure 09: Global Clinical Trials Outsourcing, BPS Analysis, by Region, 2018(H), 2023(E) & 2030(F)
Figure 10: Global Clinical Trials Outsourcing, Y-O-Y Growth, by Region, 2018(H) - 2030(F)
Figure 11: Global Clinical Trials Outsourcing Attractiveness Analysis, by Region
Figure 12: North America Clinical Trials Outsourcing Value (USD Mn Forecast, 2018 – 2022
Figure 13: North America Clinical Trials Outsourcing Value (USD Mn Forecast, 2023 – 2030
Figure 14: South America Clinical Trials Outsourcing Value (USD Mn) Forecast, 2018 – 2022
Figure 15: South America Clinical Trials Outsourcing Value (USD Mn) Forecast, 2023 – 2030
Figure 16: Europe Clinical Trials Outsourcing Value (USD Mn) Forecast, 2018 – 2022
Figure 17: Europe Clinical Trials Outsourcing Value (USD Mn) Forecast, 2023 – 2030
Figure 18: Middle East and Africa Clinical Trials Outsourcing Value (USD Mn) Forecast, 2018 – 2022
LIST OF TABLES
Table 01: Global Clinical Trials Outsourcing Value (USD Mn) Forecast, By Phase of Clinical Trial, 2018(H) – 2030(F)
Table 02: Global Clinical Trials Outsourcing Value (USD Mn) Forecast, By Service Type, 2018(H) – 2030(F)
Table 03: Global Clinical Trials Outsourcing Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 04: North America Clinical Trials Outsourcing Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 05: North America Clinical Trials Outsourcing Value (USD Mn) Forecast,By Phase of Clinical Trial, 2018(H) – 2030(F)
Table 06: North America Clinical Trials Outsourcing Value (USD Mn) Forecast, By Service Type, 2018(H) – 2030(F)
Table 07: South America Clinical Trials Outsourcing Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 08: South America Clinical Trials Outsourcing Value (USD Mn) Forecast,By Phase of Clinical Trial, 2018(H) – 2030(F)
Table 09: South America Clinical Trials Outsourcing Value (USD Mn) Forecast, By Service Type, 2018(H) – 2030(F)
Table 10: Europe Clinical Trials Outsourcing Value (USD Mn) and Forecast, by Country, 2018(H) – 2030(F)
Table 11: Europe Clinical Trials Outsourcing Value (USD Mn) Forecast, By Phase of Clinical Trial, 2018(H) – 2030(F)
Table 12: Europe Clinical Trials Outsourcing Value (USD Mn) Forecast, By Service Type EndUser, 2018(H) – 2030(F)
Table 13: Middle East and Africa Clinical Trials Outsourcing Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 14: Middle East and Africa Clinical Trials Outsourcing Value (USD Mn) Forecast, By Phase of Clinical Trial, 2018(H) – 2030(F)
Table 15: Middle East and Africa Clinical Trials Outsourcing Value (USD Mn) Forecast, By Service Type, 2018(H) – 2030(F)
Table 16: Asia-Pacific Clinical Trials Outsourcing Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 17: Asia-Pacific Clinical Trials Outsourcing Value (USD Mn) Forecast, By Phase of Clinical Trial, 2018(H) – 2030(F)
Table 18: Asia-Pacific Clinical Trials Outsourcing Value (USD Mn) Forecast, By Service Type, 2018(H) – 2030(F)
Direct Purchase
Your perfect start with Stats And ResearchWant to customize this report?
This report can be customized according to your requirements. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
You may also be lnterested in..
Stats And Research ™ Copyright © 2025 .